| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 61 | 2022 | 1070 | 9.790 |
Why?
|
| Hematinics | 28 | 2020 | 52 | 9.340 |
Why?
|
| Prostatic Neoplasms | 63 | 2021 | 778 | 8.570 |
Why?
|
| Biosimilar Pharmaceuticals | 13 | 2023 | 25 | 8.240 |
Why?
|
| Neoplasms | 70 | 2021 | 1667 | 8.120 |
Why?
|
| Anemia | 27 | 2021 | 104 | 7.380 |
Why?
|
| United States Food and Drug Administration | 33 | 2022 | 131 | 5.890 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 18 | 2022 | 148 | 5.840 |
Why?
|
| Erythropoietin | 28 | 2020 | 96 | 5.600 |
Why?
|
| Drug Industry | 16 | 2023 | 54 | 5.230 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 10 | 2022 | 18 | 4.940 |
Why?
|
| Drug Approval | 17 | 2022 | 50 | 4.800 |
Why?
|
| Pneumonia, Pneumocystis | 39 | 2010 | 57 | 4.440 |
Why?
|
| Neutropenia | 19 | 2019 | 72 | 4.420 |
Why?
|
| Humans | 452 | 2023 | 68618 | 4.330 |
Why?
|
| Drug Costs | 14 | 2023 | 87 | 4.270 |
Why?
|
| United States | 143 | 2022 | 7367 | 4.200 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 21 | 2019 | 42 | 3.970 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 16 | 2017 | 21 | 3.970 |
Why?
|
| AIDS-Related Opportunistic Infections | 33 | 2010 | 85 | 3.830 |
Why?
|
| Medical Oncology | 23 | 2020 | 110 | 3.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 16 | 2013 | 74 | 3.150 |
Why?
|
| Ticlopidine | 14 | 2022 | 118 | 2.610 |
Why?
|
| Prostate-Specific Antigen | 11 | 2018 | 138 | 2.530 |
Why?
|
| Male | 211 | 2021 | 37321 | 2.350 |
Why?
|
| Clinical Trials as Topic | 22 | 2022 | 848 | 2.310 |
Why?
|
| Health Care Costs | 22 | 2018 | 346 | 2.270 |
Why?
|
| Mass Screening | 22 | 2020 | 843 | 2.080 |
Why?
|
| Platelet Aggregation Inhibitors | 12 | 2019 | 373 | 2.070 |
Why?
|
| Practice Patterns, Physicians' | 16 | 2020 | 504 | 2.030 |
Why?
|
| Red-Cell Aplasia, Pure | 7 | 2018 | 13 | 2.000 |
Why?
|
| Rituximab | 8 | 2022 | 61 | 1.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2013 | 468 | 1.960 |
Why?
|
| Fluoroquinolones | 4 | 2022 | 49 | 1.940 |
Why?
|
| Thalidomide | 5 | 2022 | 24 | 1.940 |
Why?
|
| Middle Aged | 148 | 2020 | 21147 | 1.930 |
Why?
|
| Cost-Benefit Analysis | 38 | 2017 | 504 | 1.920 |
Why?
|
| Pharmacovigilance | 4 | 2022 | 5 | 1.920 |
Why?
|
| Aged | 122 | 2022 | 14862 | 1.900 |
Why?
|
| Quality of Life | 32 | 2016 | 1515 | 1.900 |
Why?
|
| Female | 170 | 2022 | 38074 | 1.880 |
Why?
|
| Acquired Immunodeficiency Syndrome | 22 | 2016 | 123 | 1.840 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2016 | 73 | 1.810 |
Why?
|
| Colorectal Neoplasms | 17 | 2017 | 561 | 1.800 |
Why?
|
| Filgrastim | 7 | 2020 | 22 | 1.790 |
Why?
|
| Veterans | 16 | 2021 | 904 | 1.790 |
Why?
|
| Immunologic Factors | 5 | 2017 | 87 | 1.720 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2018 | 161 | 1.710 |
Why?
|
| Drugs, Generic | 3 | 2017 | 17 | 1.690 |
Why?
|
| Anti-Bacterial Agents | 15 | 2022 | 1026 | 1.680 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 3 | 2022 | 7 | 1.650 |
Why?
|
| Medicaid | 11 | 2017 | 302 | 1.640 |
Why?
|
| Health Policy | 11 | 2022 | 221 | 1.580 |
Why?
|
| Antineoplastic Agents, Hormonal | 13 | 2016 | 99 | 1.550 |
Why?
|
| Adult | 129 | 2021 | 21403 | 1.530 |
Why?
|
| Breast Neoplasms | 14 | 2017 | 1536 | 1.520 |
Why?
|
| HIV Infections | 21 | 2016 | 791 | 1.500 |
Why?
|
| Anti-HIV Agents | 9 | 2016 | 135 | 1.500 |
Why?
|
| Thrombosis | 3 | 2022 | 218 | 1.490 |
Why?
|
| Conflict of Interest | 4 | 2016 | 48 | 1.480 |
Why?
|
| Androgen Antagonists | 12 | 2018 | 45 | 1.480 |
Why?
|
| Anaphylaxis | 3 | 2018 | 43 | 1.470 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 1.460 |
Why?
|
| Quality of Health Care | 16 | 2017 | 322 | 1.370 |
Why?
|
| Databases, Factual | 10 | 2016 | 622 | 1.330 |
Why?
|
| Hospitalization | 23 | 2016 | 978 | 1.320 |
Why?
|
| Venous Thromboembolism | 5 | 2020 | 117 | 1.320 |
Why?
|
| Hematologic Neoplasms | 6 | 2016 | 37 | 1.320 |
Why?
|
| Health Services Accessibility | 11 | 2016 | 581 | 1.300 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 11 | 2009 | 101 | 1.300 |
Why?
|
| Research Support as Topic | 6 | 2016 | 58 | 1.300 |
Why?
|
| Educational Status | 12 | 2013 | 273 | 1.290 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2019 | 44 | 1.260 |
Why?
|
| Drug Labeling | 7 | 2020 | 32 | 1.250 |
Why?
|
| Thromboembolism | 6 | 2016 | 91 | 1.240 |
Why?
|
| Insurance, Health, Reimbursement | 8 | 2008 | 47 | 1.240 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2016 | 116 | 1.220 |
Why?
|
| Costs and Cost Analysis | 24 | 2014 | 193 | 1.220 |
Why?
|
| Recombinant Proteins | 27 | 2017 | 742 | 1.210 |
Why?
|
| Health Status | 11 | 2021 | 429 | 1.170 |
Why?
|
| Drug Utilization | 7 | 2019 | 119 | 1.150 |
Why?
|
| ADAM Proteins | 7 | 2015 | 53 | 1.140 |
Why?
|
| Off-Label Use | 3 | 2018 | 17 | 1.130 |
Why?
|
| Fever | 5 | 2013 | 96 | 1.110 |
Why?
|
| United States Department of Veterans Affairs | 14 | 2020 | 307 | 1.100 |
Why?
|
| Aged, 80 and over | 40 | 2021 | 4848 | 1.090 |
Why?
|
| Prostatectomy | 7 | 2018 | 87 | 1.090 |
Why?
|
| Biological Products | 2 | 2018 | 78 | 1.090 |
Why?
|
| Fibrinolytic Agents | 5 | 2012 | 377 | 1.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2016 | 245 | 1.060 |
Why?
|
| Practice Guidelines as Topic | 11 | 2017 | 772 | 1.050 |
Why?
|
| Medicare | 12 | 2022 | 319 | 1.050 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2021 | 446 | 1.040 |
Why?
|
| Watchful Waiting | 3 | 2020 | 25 | 1.030 |
Why?
|
| Hospital Mortality | 18 | 2010 | 384 | 1.030 |
Why?
|
| Cost Savings | 5 | 2019 | 110 | 1.020 |
Why?
|
| Antibodies, Monoclonal | 5 | 2018 | 511 | 1.000 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2015 | 64 | 0.970 |
Why?
|
| Product Surveillance, Postmarketing | 5 | 2009 | 17 | 0.960 |
Why?
|
| Peptides | 4 | 2018 | 455 | 0.960 |
Why?
|
| Patient Selection | 12 | 2013 | 592 | 0.950 |
Why?
|
| Hemorrhage | 3 | 2019 | 328 | 0.950 |
Why?
|
| Immunoconjugates | 2 | 2014 | 26 | 0.940 |
Why?
|
| Clinical Trials, Phase III as Topic | 10 | 2009 | 84 | 0.940 |
Why?
|
| Delivery of Health Care | 11 | 2019 | 445 | 0.920 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2014 | 931 | 0.920 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 468 | 0.910 |
Why?
|
| Orphan Drug Production | 2 | 2016 | 3 | 0.910 |
Why?
|
| Treatment Outcome | 40 | 2020 | 7029 | 0.910 |
Why?
|
| Access to Information | 2 | 2014 | 21 | 0.900 |
Why?
|
| Epoetin Alfa | 11 | 2021 | 23 | 0.890 |
Why?
|
| Poverty | 10 | 2012 | 219 | 0.890 |
Why?
|
| Health Education | 11 | 2015 | 279 | 0.880 |
Why?
|
| Lymphoma | 6 | 2013 | 116 | 0.870 |
Why?
|
| Hospitals, Veterans | 10 | 2010 | 147 | 0.860 |
Why?
|
| Fraud | 3 | 2011 | 8 | 0.850 |
Why?
|
| Health Services | 5 | 2013 | 87 | 0.840 |
Why?
|
| Incidence | 17 | 2021 | 1603 | 0.840 |
Why?
|
| Healthcare Disparities | 4 | 2016 | 378 | 0.830 |
Why?
|
| Urology | 3 | 2019 | 31 | 0.830 |
Why?
|
| Hematologic Agents | 2 | 2019 | 11 | 0.830 |
Why?
|
| Levofloxacin | 4 | 2020 | 23 | 0.820 |
Why?
|
| Warfarin | 2 | 2012 | 93 | 0.820 |
Why?
|
| Government Regulation | 2 | 2016 | 46 | 0.820 |
Why?
|
| Ovarian Neoplasms | 8 | 2004 | 267 | 0.810 |
Why?
|
| Pharmaceutical Preparations | 4 | 2023 | 101 | 0.810 |
Why?
|
| Abortion, Spontaneous | 1 | 2022 | 17 | 0.800 |
Why?
|
| Health Personnel | 5 | 2010 | 286 | 0.800 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 122 | 0.800 |
Why?
|
| Pyrimidines | 4 | 2019 | 178 | 0.800 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2022 | 20 | 0.800 |
Why?
|
| Information Dissemination | 2 | 2022 | 113 | 0.800 |
Why?
|
| Risk Factors | 32 | 2021 | 5731 | 0.800 |
Why?
|
| Survival Rate | 21 | 2017 | 1056 | 0.790 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2021 | 33 | 0.780 |
Why?
|
| Medication Adherence | 2 | 2016 | 335 | 0.750 |
Why?
|
| Cost of Illness | 7 | 2014 | 206 | 0.750 |
Why?
|
| Patient Education as Topic | 10 | 2013 | 425 | 0.750 |
Why?
|
| Social Media | 1 | 2022 | 59 | 0.730 |
Why?
|
| Public Health | 2 | 2016 | 201 | 0.730 |
Why?
|
| Japan | 8 | 2020 | 68 | 0.730 |
Why?
|
| Prescription Drugs | 2 | 2011 | 71 | 0.720 |
Why?
|
| Neoplasm Staging | 13 | 2015 | 800 | 0.720 |
Why?
|
| Benchmarking | 1 | 2020 | 91 | 0.720 |
Why?
|
| Kidney Failure, Chronic | 3 | 2015 | 365 | 0.720 |
Why?
|
| Bone Marrow Transplantation | 11 | 1999 | 149 | 0.720 |
Why?
|
| Chicago | 18 | 2012 | 30 | 0.710 |
Why?
|
| Retrospective Studies | 39 | 2021 | 7277 | 0.710 |
Why?
|
| Machine Learning | 1 | 2022 | 170 | 0.710 |
Why?
|
| Adenocarcinoma | 6 | 2015 | 475 | 0.700 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2020 | 28 | 0.700 |
Why?
|
| Immunotherapy | 1 | 2022 | 215 | 0.700 |
Why?
|
| Bevacizumab | 2 | 2020 | 34 | 0.700 |
Why?
|
| Premature Birth | 1 | 2022 | 150 | 0.690 |
Why?
|
| ADAMTS13 Protein | 9 | 2017 | 10 | 0.690 |
Why?
|
| Early Detection of Cancer | 9 | 2017 | 454 | 0.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 300 | 0.690 |
Why?
|
| Health Knowledge, Attitudes, Practice | 12 | 2015 | 767 | 0.690 |
Why?
|
| Anthrax | 3 | 2012 | 6 | 0.690 |
Why?
|
| Natalizumab | 2 | 2017 | 6 | 0.680 |
Why?
|
| Drugs, Investigational | 2 | 2014 | 18 | 0.660 |
Why?
|
| Pyrazoles | 2 | 2019 | 190 | 0.660 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 14 | 0.650 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2016 | 7 | 0.650 |
Why?
|
| Root Cause Analysis | 1 | 2018 | 2 | 0.650 |
Why?
|
| Receptors, Erythropoietin | 2 | 2016 | 9 | 0.650 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2010 | 138 | 0.650 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2011 | 33 | 0.650 |
Why?
|
| Risk Assessment | 19 | 2021 | 2007 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 151 | 0.640 |
Why?
|
| Long Term Adverse Effects | 1 | 2018 | 6 | 0.640 |
Why?
|
| Cohort Studies | 22 | 2018 | 2358 | 0.630 |
Why?
|
| Friction | 1 | 2018 | 16 | 0.630 |
Why?
|
| Behavioral Symptoms | 1 | 2018 | 32 | 0.620 |
Why?
|
| Renal Dialysis | 3 | 2016 | 174 | 0.620 |
Why?
|
| Prognosis | 18 | 2021 | 2093 | 0.620 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2016 | 2 | 0.610 |
Why?
|
| Publishing | 1 | 2019 | 89 | 0.610 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2005 | 82 | 0.610 |
Why?
|
| Patient Satisfaction | 8 | 2015 | 378 | 0.610 |
Why?
|
| Azithromycin | 2 | 2014 | 13 | 0.610 |
Why?
|
| Severity of Illness Index | 19 | 2018 | 1851 | 0.600 |
Why?
|
| Mucormycosis | 2 | 2015 | 6 | 0.600 |
Why?
|
| Insurance, Health | 10 | 2013 | 201 | 0.600 |
Why?
|
| Models, Economic | 6 | 2009 | 69 | 0.600 |
Why?
|
| Policy Making | 6 | 2020 | 51 | 0.600 |
Why?
|
| Health Expenditures | 7 | 2022 | 170 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 331 | 0.590 |
Why?
|
| Terminal Care | 2 | 2015 | 92 | 0.590 |
Why?
|
| Hepatitis B | 3 | 2020 | 42 | 0.590 |
Why?
|
| Aminoglycosides | 2 | 2016 | 54 | 0.590 |
Why?
|
| Decision Making | 12 | 2020 | 410 | 0.580 |
Why?
|
| Adolescent | 30 | 2020 | 8912 | 0.580 |
Why?
|
| Suicide | 1 | 2018 | 116 | 0.580 |
Why?
|
| Age Factors | 13 | 2017 | 1864 | 0.580 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2016 | 52 | 0.570 |
Why?
|
| Research | 1 | 2018 | 214 | 0.570 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 62 | 0.570 |
Why?
|
| Head and Neck Neoplasms | 3 | 2009 | 561 | 0.560 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 1173 | 0.560 |
Why?
|
| Penile Implantation | 1 | 2016 | 2 | 0.550 |
Why?
|
| Darbepoetin alfa | 9 | 2017 | 13 | 0.550 |
Why?
|
| Patient Participation | 7 | 2013 | 146 | 0.550 |
Why?
|
| Penile Erection | 1 | 2016 | 18 | 0.550 |
Why?
|
| Anticoagulants | 4 | 2019 | 356 | 0.550 |
Why?
|
| Life Expectancy | 4 | 2012 | 51 | 0.550 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 18 | 0.550 |
Why?
|
| Erectile Dysfunction | 1 | 2016 | 22 | 0.540 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 8 | 0.540 |
Why?
|
| Population Surveillance | 4 | 2010 | 285 | 0.540 |
Why?
|
| Colonoscopy | 6 | 2016 | 156 | 0.540 |
Why?
|
| Oxycodone | 1 | 2016 | 10 | 0.540 |
Why?
|
| Paclitaxel | 4 | 2011 | 140 | 0.540 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 25 | 0.540 |
Why?
|
| Flutamide | 5 | 2001 | 10 | 0.540 |
Why?
|
| Professional Staff Committees | 2 | 2009 | 11 | 0.530 |
Why?
|
| Fusariosis | 1 | 2015 | 1 | 0.530 |
Why?
|
| Surveys and Questionnaires | 20 | 2021 | 2800 | 0.530 |
Why?
|
| Time Factors | 21 | 2017 | 4655 | 0.530 |
Why?
|
| Nevirapine | 3 | 2009 | 7 | 0.530 |
Why?
|
| Guidelines as Topic | 5 | 2011 | 123 | 0.530 |
Why?
|
| Phenylthiohydantoin | 2 | 2015 | 12 | 0.530 |
Why?
|
| Multiple Sclerosis | 1 | 2017 | 132 | 0.520 |
Why?
|
| Tendon Injuries | 1 | 2015 | 9 | 0.520 |
Why?
|
| Safety | 1 | 2016 | 145 | 0.520 |
Why?
|
| Compassionate Use Trials | 1 | 2015 | 2 | 0.520 |
Why?
|
| Health Care Surveys | 11 | 2019 | 239 | 0.520 |
Why?
|
| Autoantibodies | 5 | 2015 | 434 | 0.520 |
Why?
|
| Europe | 5 | 2020 | 196 | 0.520 |
Why?
|
| Terminally Ill | 1 | 2015 | 17 | 0.520 |
Why?
|
| South Carolina | 9 | 2021 | 2752 | 0.510 |
Why?
|
| Insurance Coverage | 3 | 2013 | 99 | 0.510 |
Why?
|
| Polyethylene Glycols | 6 | 2020 | 149 | 0.500 |
Why?
|
| Fee-for-Service Plans | 6 | 2022 | 24 | 0.500 |
Why?
|
| Long QT Syndrome | 1 | 2014 | 14 | 0.490 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 30 | 0.490 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2012 | 106 | 0.490 |
Why?
|
| Logistic Models | 15 | 2017 | 1420 | 0.480 |
Why?
|
| Patient Isolation | 4 | 2005 | 35 | 0.480 |
Why?
|
| Death | 1 | 2014 | 38 | 0.480 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 3 | 2012 | 14 | 0.480 |
Why?
|
| Chronic Pain | 1 | 2016 | 110 | 0.480 |
Why?
|
| Hypotension | 2 | 2014 | 74 | 0.470 |
Why?
|
| Carcinoma, Small Cell | 2 | 2005 | 53 | 0.470 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 8 | 0.470 |
Why?
|
| Registries | 8 | 2016 | 733 | 0.470 |
Why?
|
| Stents | 5 | 2007 | 657 | 0.460 |
Why?
|
| Thrombophilia | 1 | 2014 | 21 | 0.460 |
Why?
|
| Primary Prevention | 2 | 2013 | 115 | 0.460 |
Why?
|
| Attitude of Health Personnel | 5 | 2020 | 442 | 0.460 |
Why?
|
| Drug Utilization Review | 3 | 2010 | 19 | 0.460 |
Why?
|
| Community-Acquired Infections | 4 | 2013 | 46 | 0.450 |
Why?
|
| Follow-Up Studies | 16 | 2016 | 3259 | 0.450 |
Why?
|
| Iron | 1 | 2015 | 197 | 0.450 |
Why?
|
| Melanoma | 1 | 2017 | 335 | 0.450 |
Why?
|
| Leuprolide | 2 | 2013 | 6 | 0.450 |
Why?
|
| Socioeconomic Factors | 9 | 2013 | 955 | 0.440 |
Why?
|
| Visually Impaired Persons | 1 | 2013 | 2 | 0.440 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2000 | 16 | 0.440 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2013 | 14 | 0.440 |
Why?
|
| California | 8 | 2017 | 99 | 0.430 |
Why?
|
| Thienopyridines | 1 | 2012 | 3 | 0.430 |
Why?
|
| Football | 1 | 2013 | 25 | 0.430 |
Why?
|
| Ophthalmology | 1 | 2013 | 39 | 0.430 |
Why?
|
| Hemostasis | 1 | 2012 | 32 | 0.430 |
Why?
|
| Plasma Exchange | 6 | 2017 | 18 | 0.430 |
Why?
|
| Bhopal Accidental Release | 1 | 2012 | 2 | 0.420 |
Why?
|
| Transfusion Reaction | 2 | 2007 | 33 | 0.420 |
Why?
|
| Office Visits | 1 | 2013 | 83 | 0.420 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2012 | 16 | 0.420 |
Why?
|
| Reye Syndrome | 1 | 2012 | 11 | 0.420 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2012 | 14 | 0.420 |
Why?
|
| Ambulatory Care | 6 | 2012 | 340 | 0.420 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 83 | 0.420 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 48 | 0.420 |
Why?
|
| Vision Disorders | 1 | 2013 | 94 | 0.410 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 191 | 0.410 |
Why?
|
| Taxoids | 2 | 2014 | 41 | 0.410 |
Why?
|
| Colony-Stimulating Factors | 4 | 2007 | 19 | 0.400 |
Why?
|
| Virus Activation | 3 | 2019 | 15 | 0.400 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 92 | 0.400 |
Why?
|
| Survival Analysis | 13 | 2021 | 714 | 0.400 |
Why?
|
| Testosterone | 1 | 2012 | 96 | 0.400 |
Why?
|
| Atrial Fibrillation | 2 | 2012 | 249 | 0.400 |
Why?
|
| Doxorubicin | 6 | 2011 | 231 | 0.400 |
Why?
|
| Anthrax Vaccines | 2 | 2012 | 5 | 0.400 |
Why?
|
| Bioterrorism | 2 | 2012 | 12 | 0.390 |
Why?
|
| Genetic Variation | 2 | 2008 | 220 | 0.390 |
Why?
|
| Medication Errors | 2 | 2010 | 116 | 0.390 |
Why?
|
| Occult Blood | 7 | 2013 | 48 | 0.390 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 299 | 0.390 |
Why?
|
| Prostate | 1 | 2012 | 116 | 0.390 |
Why?
|
| Daunorubicin | 3 | 2004 | 20 | 0.390 |
Why?
|
| Managed Care Programs | 6 | 2004 | 45 | 0.390 |
Why?
|
| Carbapenems | 1 | 2011 | 7 | 0.380 |
Why?
|
| Hepatitis C | 2 | 2015 | 114 | 0.380 |
Why?
|
| Sarcoma, Kaposi | 3 | 2004 | 25 | 0.380 |
Why?
|
| Evidence-Based Medicine | 8 | 2019 | 438 | 0.380 |
Why?
|
| Amyloid beta-Peptides | 1 | 2013 | 191 | 0.380 |
Why?
|
| Cause of Death | 2 | 2010 | 241 | 0.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2008 | 36 | 0.380 |
Why?
|
| Cross Infection | 4 | 2000 | 195 | 0.380 |
Why?
|
| Memory | 1 | 2013 | 214 | 0.380 |
Why?
|
| Combined Modality Therapy | 13 | 2016 | 951 | 0.380 |
Why?
|
| Premedication | 1 | 2011 | 49 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2016 | 129 | 0.380 |
Why?
|
| Prospective Studies | 18 | 2018 | 3705 | 0.380 |
Why?
|
| Multicenter Studies as Topic | 7 | 2009 | 186 | 0.370 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 498 | 0.370 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 2279 | 0.360 |
Why?
|
| Health Promotion | 4 | 2015 | 407 | 0.360 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 508 | 0.360 |
Why?
|
| Health Services Misuse | 1 | 2010 | 15 | 0.360 |
Why?
|
| Biomedical Research | 2 | 2007 | 310 | 0.360 |
Why?
|
| Multiple Myeloma | 3 | 2006 | 92 | 0.360 |
Why?
|
| Peptide Fragments | 1 | 2013 | 483 | 0.360 |
Why?
|
| Quinazolines | 2 | 2002 | 70 | 0.360 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2010 | 64 | 0.360 |
Why?
|
| Health Services Research | 7 | 2013 | 209 | 0.360 |
Why?
|
| Amifostine | 2 | 2001 | 3 | 0.360 |
Why?
|
| Women's Health | 3 | 2016 | 148 | 0.360 |
Why?
|
| Disasters | 1 | 2012 | 204 | 0.360 |
Why?
|
| Young Adult | 9 | 2021 | 5717 | 0.360 |
Why?
|
| Physician's Role | 2 | 2004 | 116 | 0.360 |
Why?
|
| Hospitals | 6 | 2007 | 265 | 0.350 |
Why?
|
| Urologists | 2 | 2020 | 7 | 0.350 |
Why?
|
| Refugees | 2 | 2000 | 9 | 0.350 |
Why?
|
| Hodgkin Disease | 5 | 2014 | 27 | 0.350 |
Why?
|
| Drug Substitution | 2 | 2020 | 19 | 0.350 |
Why?
|
| Drug Interactions | 2 | 2010 | 289 | 0.350 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2007 | 69 | 0.350 |
Why?
|
| Comorbidity | 5 | 2010 | 1426 | 0.350 |
Why?
|
| Child | 15 | 2018 | 6405 | 0.350 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 114 | 0.340 |
Why?
|
| Multivariate Analysis | 13 | 2016 | 1046 | 0.340 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2000 | 70 | 0.340 |
Why?
|
| Patient Compliance | 6 | 2016 | 402 | 0.340 |
Why?
|
| Intensive Care Units | 6 | 2007 | 344 | 0.340 |
Why?
|
| Cancer Care Facilities | 1 | 2009 | 32 | 0.340 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2009 | 41 | 0.340 |
Why?
|
| Population Groups | 1 | 2009 | 16 | 0.330 |
Why?
|
| HIV Seronegativity | 1 | 2009 | 11 | 0.330 |
Why?
|
| Proxy | 1 | 2009 | 8 | 0.330 |
Why?
|
| Contrast Media | 1 | 2012 | 595 | 0.330 |
Why?
|
| Jaw | 1 | 2008 | 4 | 0.330 |
Why?
|
| Psychometrics | 4 | 2005 | 514 | 0.330 |
Why?
|
| Osteonecrosis | 1 | 2008 | 20 | 0.320 |
Why?
|
| Patients | 1 | 2009 | 69 | 0.320 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 1999 | 59 | 0.320 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2006 | 58 | 0.320 |
Why?
|
| Seizures | 1 | 2011 | 279 | 0.320 |
Why?
|
| Pharyngitis | 1 | 2008 | 10 | 0.320 |
Why?
|
| Mucositis | 1 | 2008 | 9 | 0.320 |
Why?
|
| Odds Ratio | 12 | 2018 | 880 | 0.320 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2005 | 61 | 0.320 |
Why?
|
| Diphosphonates | 1 | 2008 | 39 | 0.320 |
Why?
|
| Community Networks | 1 | 2009 | 96 | 0.320 |
Why?
|
| Radiation Injuries | 2 | 2008 | 97 | 0.320 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2008 | 2 | 0.320 |
Why?
|
| Risk | 7 | 2016 | 563 | 0.320 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 110 | 0.310 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 2006 | 22 | 0.310 |
Why?
|
| Medically Underserved Area | 3 | 2015 | 85 | 0.310 |
Why?
|
| Orchiectomy | 8 | 2013 | 25 | 0.310 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 22 | 0.310 |
Why?
|
| Marketing of Health Services | 2 | 2005 | 18 | 0.310 |
Why?
|
| Adenine | 2 | 2019 | 46 | 0.300 |
Why?
|
| Confidentiality | 2 | 2006 | 62 | 0.300 |
Why?
|
| Sigmoidoscopy | 5 | 2010 | 38 | 0.300 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2005 | 41 | 0.300 |
Why?
|
| Hemophilia A | 1 | 2007 | 9 | 0.300 |
Why?
|
| Substance Abuse, Intravenous | 5 | 1998 | 30 | 0.300 |
Why?
|
| Health Maintenance Organizations | 3 | 2003 | 22 | 0.300 |
Why?
|
| Sex Factors | 7 | 2016 | 1266 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2007 | 29 | 0.290 |
Why?
|
| Piperidines | 2 | 2019 | 123 | 0.290 |
Why?
|
| Regression Analysis | 11 | 2013 | 737 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2002 | 300 | 0.290 |
Why?
|
| Piperacillin | 1 | 2007 | 6 | 0.290 |
Why?
|
| Economics, Pharmaceutical | 3 | 2002 | 5 | 0.290 |
Why?
|
| Emergency Treatment | 1 | 2007 | 52 | 0.290 |
Why?
|
| History, 21st Century | 4 | 2016 | 127 | 0.290 |
Why?
|
| RNA Helicases | 1 | 2006 | 1 | 0.290 |
Why?
|
| Reproducibility of Results | 9 | 2016 | 2077 | 0.290 |
Why?
|
| Ataxia | 1 | 2006 | 11 | 0.280 |
Why?
|
| Societies, Medical | 5 | 2007 | 403 | 0.280 |
Why?
|
| Tremor | 1 | 2006 | 16 | 0.280 |
Why?
|
| Outpatients | 2 | 2005 | 127 | 0.280 |
Why?
|
| Neoplasm Metastasis | 10 | 2014 | 306 | 0.280 |
Why?
|
| Respiratory Insufficiency | 2 | 2000 | 76 | 0.280 |
Why?
|
| Macular Degeneration | 2 | 2021 | 75 | 0.280 |
Why?
|
| Contraceptives, Oral | 2 | 2016 | 28 | 0.280 |
Why?
|
| Health Care Reform | 4 | 2000 | 62 | 0.280 |
Why?
|
| Hospitals, Urban | 5 | 2010 | 46 | 0.280 |
Why?
|
| Skin | 2 | 2013 | 451 | 0.280 |
Why?
|
| Program Development | 2 | 2005 | 240 | 0.270 |
Why?
|
| Kidney Diseases | 3 | 2005 | 307 | 0.270 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 158 | 0.270 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2006 | 13 | 0.270 |
Why?
|
| Federal Government | 1 | 2005 | 13 | 0.270 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2005 | 9 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2006 | 77 | 0.270 |
Why?
|
| Pneumonia | 1 | 2007 | 110 | 0.260 |
Why?
|
| Deoxycytidine | 1 | 2006 | 83 | 0.260 |
Why?
|
| von Willebrand Factor | 1 | 2005 | 47 | 0.260 |
Why?
|
| Morbidity | 3 | 2009 | 130 | 0.260 |
Why?
|
| Community Health Services | 1 | 2007 | 141 | 0.260 |
Why?
|
| Pilot Projects | 8 | 2008 | 1342 | 0.260 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 127 | 0.260 |
Why?
|
| Spouses | 2 | 2009 | 51 | 0.260 |
Why?
|
| Syndrome | 2 | 2022 | 255 | 0.260 |
Why?
|
| Disease Management | 2 | 2018 | 248 | 0.260 |
Why?
|
| Emergency Medical Services | 2 | 2012 | 225 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2223 | 0.260 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2009 | 131 | 0.260 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 792 | 0.260 |
Why?
|
| Pyridines | 1 | 2007 | 261 | 0.260 |
Why?
|
| Disease-Free Survival | 7 | 2016 | 349 | 0.260 |
Why?
|
| Pharmaceutical Services | 1 | 2005 | 47 | 0.260 |
Why?
|
| Imidazoles | 2 | 2008 | 175 | 0.250 |
Why?
|
| Reimbursement Mechanisms | 2 | 2010 | 37 | 0.250 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2005 | 1 | 0.250 |
Why?
|
| Health Services Needs and Demand | 5 | 2017 | 149 | 0.250 |
Why?
|
| Ciprofloxacin | 3 | 2020 | 30 | 0.250 |
Why?
|
| Anthracyclines | 1 | 2004 | 9 | 0.250 |
Why?
|
| Mammography | 4 | 2015 | 310 | 0.250 |
Why?
|
| Quality Improvement | 2 | 2019 | 413 | 0.250 |
Why?
|
| Tissue Donors | 1 | 2006 | 195 | 0.250 |
Why?
|
| Program Evaluation | 5 | 2016 | 502 | 0.250 |
Why?
|
| Transplantation, Homologous | 3 | 2007 | 242 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 786 | 0.240 |
Why?
|
| Needs Assessment | 2 | 2010 | 186 | 0.240 |
Why?
|
| Interviews as Topic | 4 | 2019 | 392 | 0.240 |
Why?
|
| Community Health Centers | 2 | 2015 | 26 | 0.240 |
Why?
|
| Medically Uninsured | 2 | 2016 | 99 | 0.240 |
Why?
|
| Minority Groups | 3 | 2002 | 197 | 0.230 |
Why?
|
| Disease Outbreaks | 4 | 2000 | 83 | 0.230 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 172 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2017 | 186 | 0.230 |
Why?
|
| Emotions | 4 | 2014 | 244 | 0.230 |
Why?
|
| Splenectomy | 2 | 2002 | 40 | 0.220 |
Why?
|
| Acute Disease | 5 | 2015 | 658 | 0.220 |
Why?
|
| Canada | 3 | 2019 | 267 | 0.220 |
Why?
|
| Data Collection | 8 | 2003 | 420 | 0.220 |
Why?
|
| Drug Hypersensitivity | 2 | 2018 | 35 | 0.220 |
Why?
|
| Social Class | 6 | 2020 | 127 | 0.220 |
Why?
|
| Endothelial Cells | 2 | 2005 | 384 | 0.220 |
Why?
|
| Length of Stay | 8 | 2000 | 780 | 0.220 |
Why?
|
| Carcinoma | 3 | 2003 | 215 | 0.220 |
Why?
|
| Adalimumab | 1 | 2023 | 16 | 0.220 |
Why?
|
| Benzamides | 3 | 2015 | 156 | 0.220 |
Why?
|
| Los Angeles | 9 | 2000 | 30 | 0.220 |
Why?
|
| Quality Control | 2 | 2018 | 81 | 0.220 |
Why?
|
| Aortic Aneurysm | 2 | 2020 | 77 | 0.220 |
Why?
|
| Interferon-alpha | 2 | 2002 | 46 | 0.210 |
Why?
|
| Primary Health Care | 2 | 2007 | 703 | 0.210 |
Why?
|
| Hydroxyurea | 2 | 2002 | 57 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2003 | 1615 | 0.210 |
Why?
|
| Animals | 10 | 2021 | 20881 | 0.210 |
Why?
|
| Child, Preschool | 9 | 2015 | 3187 | 0.210 |
Why?
|
| SEER Program | 3 | 2017 | 153 | 0.210 |
Why?
|
| European Union | 2 | 2019 | 4 | 0.210 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 12 | 0.210 |
Why?
|
| Thrombocytosis | 1 | 2002 | 7 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 189 | 0.210 |
Why?
|
| Lung | 3 | 2007 | 849 | 0.210 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2013 | 155 | 0.210 |
Why?
|
| Health Behavior | 3 | 2002 | 458 | 0.210 |
Why?
|
| Recurrence | 5 | 2010 | 948 | 0.210 |
Why?
|
| Medical Records | 4 | 2001 | 121 | 0.200 |
Why?
|
| Denmark | 1 | 2022 | 24 | 0.200 |
Why?
|
| Medical Informatics | 2 | 2013 | 71 | 0.200 |
Why?
|
| Stillbirth | 1 | 2022 | 12 | 0.200 |
Why?
|
| Observer Variation | 2 | 2016 | 330 | 0.200 |
Why?
|
| Adaptation, Psychological | 3 | 2009 | 447 | 0.200 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2021 | 10 | 0.200 |
Why?
|
| Coronary Disease | 3 | 2003 | 358 | 0.200 |
Why?
|
| Bronchoscopy | 7 | 2003 | 147 | 0.200 |
Why?
|
| Exanthema | 1 | 2021 | 30 | 0.190 |
Why?
|
| Platelet Transfusion | 2 | 2017 | 21 | 0.190 |
Why?
|
| Peer Review, Health Care | 1 | 2001 | 4 | 0.190 |
Why?
|
| Imidazolidines | 1 | 2001 | 4 | 0.190 |
Why?
|
| Mutation | 1 | 2006 | 1213 | 0.190 |
Why?
|
| Disease Progression | 10 | 2013 | 1038 | 0.190 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 18 | 0.190 |
Why?
|
| Alu Elements | 1 | 2021 | 2 | 0.190 |
Why?
|
| Selection Bias | 1 | 2001 | 23 | 0.190 |
Why?
|
| Hospitals, Public | 4 | 2005 | 22 | 0.190 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2021 | 4 | 0.190 |
Why?
|
| Antifungal Agents | 3 | 1998 | 108 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 107 | 0.190 |
Why?
|
| Trastuzumab | 1 | 2020 | 17 | 0.190 |
Why?
|
| Algorithms | 1 | 2007 | 1196 | 0.190 |
Why?
|
| Retinal Pigments | 1 | 2021 | 61 | 0.190 |
Why?
|
| Carboplatin | 1 | 2001 | 59 | 0.190 |
Why?
|
| Drug Repositioning | 1 | 2020 | 8 | 0.180 |
Why?
|
| Probability | 5 | 2007 | 245 | 0.180 |
Why?
|
| Health Resources | 6 | 1996 | 76 | 0.180 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 191 | 0.180 |
Why?
|
| Physicians | 3 | 2005 | 324 | 0.180 |
Why?
|
| Physician-Patient Relations | 5 | 2005 | 261 | 0.180 |
Why?
|
| HIV-1 | 3 | 2020 | 177 | 0.180 |
Why?
|
| Inflammasomes | 1 | 2020 | 39 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2021 | 163 | 0.180 |
Why?
|
| Censuses | 1 | 2020 | 6 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2016 | 1465 | 0.180 |
Why?
|
| Insulin Resistance | 2 | 2020 | 241 | 0.180 |
Why?
|
| Leukemia, T-Cell | 1 | 2000 | 21 | 0.180 |
Why?
|
| Breast | 1 | 2001 | 137 | 0.180 |
Why?
|
| Health Planning | 1 | 2000 | 23 | 0.180 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1999 | 3 | 0.180 |
Why?
|
| Isoantibodies | 1 | 2000 | 35 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 1 | 2000 | 38 | 0.170 |
Why?
|
| Injections, Subcutaneous | 2 | 2018 | 87 | 0.170 |
Why?
|
| Organizations, Nonprofit | 1 | 1999 | 8 | 0.170 |
Why?
|
| Coronary Thrombosis | 1 | 1999 | 45 | 0.170 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 19 | 0.170 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2020 | 66 | 0.170 |
Why?
|
| Piperazines | 2 | 2012 | 206 | 0.170 |
Why?
|
| Liver | 2 | 2007 | 1118 | 0.170 |
Why?
|
| Bone and Bones | 2 | 2012 | 145 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2012 | 248 | 0.170 |
Why?
|
| Warfare | 1 | 1999 | 58 | 0.170 |
Why?
|
| Hemoglobins | 2 | 2013 | 120 | 0.170 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 514 | 0.170 |
Why?
|
| Condoms | 2 | 2001 | 67 | 0.170 |
Why?
|
| Thrombocythemia, Essential | 1 | 1999 | 2 | 0.170 |
Why?
|
| Cytoprotection | 1 | 1999 | 39 | 0.170 |
Why?
|
| Nomograms | 1 | 2019 | 19 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2018 | 215 | 0.160 |
Why?
|
| Genes, Dominant | 3 | 2008 | 51 | 0.160 |
Why?
|
| Tungsten | 1 | 2018 | 3 | 0.160 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2018 | 4 | 0.160 |
Why?
|
| Patents as Topic | 1 | 2018 | 4 | 0.160 |
Why?
|
| Excipients | 1 | 2018 | 8 | 0.160 |
Why?
|
| Syringes | 1 | 2018 | 15 | 0.160 |
Why?
|
| Angioplasty, Balloon | 1 | 1999 | 110 | 0.160 |
Why?
|
| Practice Management, Medical | 1 | 1999 | 24 | 0.160 |
Why?
|
| Protective Agents | 1 | 1999 | 36 | 0.160 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.160 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2018 | 2 | 0.160 |
Why?
|
| Urologic Surgical Procedures | 1 | 2019 | 47 | 0.160 |
Why?
|
| Hematology | 3 | 2012 | 10 | 0.160 |
Why?
|
| Analysis of Variance | 5 | 2007 | 1040 | 0.160 |
Why?
|
| Caregivers | 2 | 2009 | 365 | 0.160 |
Why?
|
| Veterans Health | 1 | 2019 | 62 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 3 | 2005 | 57 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 1999 | 102 | 0.160 |
Why?
|
| Hospitals, Private | 3 | 2005 | 15 | 0.160 |
Why?
|
| Sex | 1 | 1998 | 7 | 0.150 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1998 | 7 | 0.150 |
Why?
|
| Editorial Policies | 1 | 2018 | 32 | 0.150 |
Why?
|
| Esophageal Achalasia | 1 | 2018 | 78 | 0.150 |
Why?
|
| Longevity | 1 | 1998 | 60 | 0.150 |
Why?
|
| Resuscitation Orders | 2 | 1997 | 12 | 0.150 |
Why?
|
| Nitriles | 2 | 2015 | 68 | 0.150 |
Why?
|
| Pregnancy | 3 | 2022 | 2334 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 268 | 0.150 |
Why?
|
| Bayes Theorem | 2 | 2020 | 307 | 0.150 |
Why?
|
| Choice Behavior | 1 | 1998 | 85 | 0.150 |
Why?
|
| Radiology | 1 | 2019 | 97 | 0.150 |
Why?
|
| Erythropoiesis | 1 | 2017 | 24 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 4 | 2002 | 177 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2019 | 211 | 0.150 |
Why?
|
| Models, Theoretical | 2 | 2004 | 384 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 1999 | 135 | 0.150 |
Why?
|
| Graft vs Host Disease | 2 | 2015 | 163 | 0.150 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 371 | 0.150 |
Why?
|
| Sexual Partners | 2 | 1995 | 106 | 0.150 |
Why?
|
| Pedigree | 2 | 2008 | 159 | 0.150 |
Why?
|
| Imagination | 1 | 1997 | 38 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2018 | 141 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 375 | 0.150 |
Why?
|
| Economic Competition | 1 | 2017 | 3 | 0.140 |
Why?
|
| Insurance Claim Review | 2 | 2010 | 39 | 0.140 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 106 | 0.140 |
Why?
|
| Medical Indigency | 1 | 2016 | 7 | 0.140 |
Why?
|
| Leukemia, Myeloid | 2 | 2007 | 39 | 0.140 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2002 | 32 | 0.140 |
Why?
|
| Therapeutic Equivalency | 1 | 2016 | 21 | 0.140 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 15 | 0.140 |
Why?
|
| Research Design | 6 | 2010 | 729 | 0.140 |
Why?
|
| Patient Care Planning | 2 | 2005 | 108 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 940 | 0.140 |
Why?
|
| Hospitals, University | 3 | 2005 | 169 | 0.140 |
Why?
|
| Penile Prosthesis | 1 | 2016 | 3 | 0.140 |
Why?
|
| Legislation as Topic | 1 | 2016 | 6 | 0.140 |
Why?
|
| Colectomy | 1 | 1997 | 64 | 0.140 |
Why?
|
| Mannose-Binding Lectin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Drug Administration Schedule | 6 | 2009 | 567 | 0.140 |
Why?
|
| Hospitals, Teaching | 1 | 1996 | 65 | 0.140 |
Why?
|
| Tuberculosis | 1 | 1997 | 77 | 0.140 |
Why?
|
| Survivors | 3 | 2014 | 256 | 0.140 |
Why?
|
| Pain Management | 1 | 2018 | 186 | 0.140 |
Why?
|
| Liposomes | 3 | 2004 | 107 | 0.130 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Focus Groups | 3 | 2007 | 247 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 1997 | 129 | 0.130 |
Why?
|
| Industry | 1 | 2016 | 28 | 0.130 |
Why?
|
| Mortality | 2 | 2009 | 163 | 0.130 |
Why?
|
| Drug Therapy | 2 | 2014 | 71 | 0.130 |
Why?
|
| Professional-Patient Relations | 2 | 2007 | 71 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2016 | 85 | 0.130 |
Why?
|
| Aspergillus | 1 | 2015 | 8 | 0.130 |
Why?
|
| Florida | 5 | 1997 | 221 | 0.130 |
Why?
|
| Progestins | 1 | 2015 | 19 | 0.130 |
Why?
|
| General Surgery | 1 | 1997 | 95 | 0.130 |
Why?
|
| Confidence Intervals | 4 | 2013 | 242 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 120 | 0.130 |
Why?
|
| Academies and Institutes | 1 | 2016 | 31 | 0.130 |
Why?
|
| Dyspepsia | 2 | 2006 | 8 | 0.130 |
Why?
|
| Germany | 2 | 2009 | 67 | 0.130 |
Why?
|
| Feasibility Studies | 5 | 2010 | 652 | 0.130 |
Why?
|
| Health Care Sector | 3 | 2007 | 26 | 0.130 |
Why?
|
| Rupture | 1 | 2015 | 29 | 0.130 |
Why?
|
| Sirolimus | 2 | 2007 | 118 | 0.130 |
Why?
|
| Priapism | 1 | 2015 | 4 | 0.130 |
Why?
|
| Mycoses | 1 | 2016 | 60 | 0.130 |
Why?
|
| Viral Load | 1 | 2016 | 127 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 629 | 0.130 |
Why?
|
| Allografts | 1 | 2015 | 63 | 0.130 |
Why?
|
| Radiotherapy | 4 | 2018 | 86 | 0.130 |
Why?
|
| Helicobacter Infections | 2 | 2006 | 40 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 170 | 0.130 |
Why?
|
| Gastrointestinal Agents | 2 | 2006 | 51 | 0.130 |
Why?
|
| Home Nursing | 1 | 1995 | 8 | 0.130 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 76 | 0.130 |
Why?
|
| Helicobacter pylori | 2 | 2006 | 54 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 117 | 0.120 |
Why?
|
| Infant | 7 | 2015 | 2891 | 0.120 |
Why?
|
| Needles | 1 | 1995 | 34 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 481 | 0.120 |
Why?
|
| Prevalence | 4 | 2018 | 1619 | 0.120 |
Why?
|
| Consensus | 1 | 2016 | 211 | 0.120 |
Why?
|
| Motivation | 1 | 2019 | 561 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2015 | 82 | 0.120 |
Why?
|
| Universities | 2 | 2013 | 191 | 0.120 |
Why?
|
| Health Literacy | 1 | 2015 | 63 | 0.120 |
Why?
|
| Laparoscopy | 1 | 1997 | 237 | 0.120 |
Why?
|
| Communication Barriers | 1 | 1995 | 48 | 0.120 |
Why?
|
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2014 | 2 | 0.120 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2005 | 130 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2016 | 954 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 16 | 0.120 |
Why?
|
| Hypertension | 2 | 2013 | 1535 | 0.120 |
Why?
|
| Factor V | 1 | 2014 | 20 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 710 | 0.120 |
Why?
|
| Cisplatin | 3 | 2000 | 192 | 0.120 |
Why?
|
| Chronic Disease | 4 | 2007 | 1330 | 0.120 |
Why?
|
| Methionine | 1 | 1993 | 36 | 0.120 |
Why?
|
| Patient Admission | 1 | 1994 | 99 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 281 | 0.120 |
Why?
|
| Angiotensinogen | 1 | 1993 | 18 | 0.120 |
Why?
|
| Disinfection | 1 | 1995 | 112 | 0.120 |
Why?
|
| Risk-Taking | 4 | 1998 | 210 | 0.120 |
Why?
|
| Regenerative Medicine | 1 | 2013 | 17 | 0.110 |
Why?
|
| Threonine | 1 | 1993 | 47 | 0.110 |
Why?
|
| Contraception | 1 | 2014 | 27 | 0.110 |
Why?
|
| Disclosure | 2 | 2007 | 45 | 0.110 |
Why?
|
| Research Personnel | 1 | 2014 | 83 | 0.110 |
Why?
|
| Inpatients | 1 | 2015 | 208 | 0.110 |
Why?
|
| Glioma | 1 | 2014 | 140 | 0.110 |
Why?
|
| Decision Trees | 4 | 2009 | 74 | 0.110 |
Why?
|
| Forecasting | 4 | 2000 | 277 | 0.110 |
Why?
|
| United Kingdom | 2 | 2005 | 152 | 0.110 |
Why?
|
| Brachytherapy | 4 | 2015 | 79 | 0.110 |
Why?
|
| Urination Disorders | 1 | 2013 | 20 | 0.110 |
Why?
|
| Substance-Related Disorders | 3 | 1997 | 1242 | 0.110 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2013 | 12 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2009 | 536 | 0.110 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2012 | 3 | 0.110 |
Why?
|
| Oncology Service, Hospital | 2 | 2010 | 9 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2004 | 15 | 0.110 |
Why?
|
| Penis | 1 | 2013 | 25 | 0.110 |
Why?
|
| Culture | 2 | 2009 | 75 | 0.110 |
Why?
|
| Glaucoma | 1 | 2013 | 50 | 0.110 |
Why?
|
| Connecticut | 1 | 2012 | 13 | 0.110 |
Why?
|
| Lawyers | 1 | 2012 | 4 | 0.110 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 67 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 47 | 0.110 |
Why?
|
| Lobbying | 1 | 2012 | 11 | 0.110 |
Why?
|
| Pentamidine | 3 | 1998 | 7 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 141 | 0.110 |
Why?
|
| Time | 1 | 2012 | 57 | 0.110 |
Why?
|
| Student Health Services | 1 | 1992 | 5 | 0.110 |
Why?
|
| Residence Characteristics | 2 | 2020 | 252 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2013 | 94 | 0.100 |
Why?
|
| Stroke | 2 | 2009 | 2163 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2013 | 86 | 0.100 |
Why?
|
| Public Opinion | 1 | 2012 | 32 | 0.100 |
Why?
|
| Genotype | 3 | 2008 | 786 | 0.100 |
Why?
|
| Thiophenes | 1 | 2012 | 76 | 0.100 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 142 | 0.100 |
Why?
|
| Amiodarone | 1 | 2012 | 21 | 0.100 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 426 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 239 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 62 | 0.100 |
Why?
|
| New York City | 5 | 2000 | 49 | 0.100 |
Why?
|
| Optic Nerve Diseases | 1 | 2012 | 31 | 0.100 |
Why?
|
| JC Virus | 1 | 2011 | 5 | 0.100 |
Why?
|
| Vaccination | 2 | 2012 | 189 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 298 | 0.100 |
Why?
|
| Wound Healing | 1 | 2013 | 260 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 649 | 0.100 |
Why?
|
| Gadolinium | 1 | 2012 | 88 | 0.100 |
Why?
|
| Cataract | 1 | 2013 | 134 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 195 | 0.100 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 98 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 364 | 0.100 |
Why?
|
| Gynecology | 2 | 2004 | 46 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1085 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2013 | 791 | 0.100 |
Why?
|
| Marketing | 1 | 2011 | 26 | 0.100 |
Why?
|
| Preventive Medicine | 2 | 2002 | 48 | 0.100 |
Why?
|
| Stress, Psychological | 2 | 1995 | 824 | 0.100 |
Why?
|
| Louisiana | 4 | 2015 | 37 | 0.100 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.100 |
Why?
|
| Depression | 1 | 2018 | 943 | 0.090 |
Why?
|
| State Government | 1 | 2011 | 34 | 0.090 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 30 | 0.090 |
Why?
|
| Aspirin | 1 | 2012 | 295 | 0.090 |
Why?
|
| Hip Fractures | 1 | 2011 | 26 | 0.090 |
Why?
|
| Sex Distribution | 3 | 2007 | 274 | 0.090 |
Why?
|
| Age Distribution | 3 | 2007 | 320 | 0.090 |
Why?
|
| Rural Population | 1 | 2013 | 398 | 0.090 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2010 | 52 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 334 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 3 | 2009 | 329 | 0.090 |
Why?
|
| Yugoslavia | 2 | 2000 | 10 | 0.090 |
Why?
|
| Nursing Staff, Hospital | 1 | 2010 | 62 | 0.090 |
Why?
|
| Vinblastine | 2 | 2007 | 40 | 0.090 |
Why?
|
| Nursing Service, Hospital | 1 | 1989 | 6 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2010 | 49 | 0.090 |
Why?
|
| Czech Republic | 1 | 2009 | 1 | 0.090 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 420 | 0.090 |
Why?
|
| Ceftriaxone | 1 | 2010 | 32 | 0.090 |
Why?
|
| Fatigue | 1 | 2010 | 132 | 0.090 |
Why?
|
| Epitopes | 1 | 2010 | 146 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2009 | 12 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2007 | 1553 | 0.090 |
Why?
|
| Urogenital Neoplasms | 1 | 2009 | 9 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1745 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 26 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2004 | 1753 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 498 | 0.080 |
Why?
|
| Pulmonary Edema | 1 | 2009 | 37 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2011 | 223 | 0.080 |
Why?
|
| Epidemiologic Studies | 1 | 2009 | 33 | 0.080 |
Why?
|
| Precipitating Factors | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sick Role | 1 | 2009 | 40 | 0.080 |
Why?
|
| Australia | 2 | 2000 | 235 | 0.080 |
Why?
|
| Tooth Extraction | 1 | 2008 | 27 | 0.080 |
Why?
|
| Intestinal Neoplasms | 1 | 2009 | 30 | 0.080 |
Why?
|
| Hong Kong | 2 | 2000 | 11 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1140 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2007 | 178 | 0.080 |
Why?
|
| Bias | 3 | 2022 | 148 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2009 | 631 | 0.080 |
Why?
|
| Reference Values | 2 | 2004 | 579 | 0.080 |
Why?
|
| Inheritance Patterns | 1 | 2008 | 7 | 0.080 |
Why?
|
| Attitude to Health | 2 | 2004 | 403 | 0.080 |
Why?
|
| Infant, Newborn | 4 | 2010 | 2455 | 0.080 |
Why?
|
| Medical Laboratory Science | 2 | 2000 | 8 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 43 | 0.080 |
Why?
|
| Electrodiagnosis | 1 | 2008 | 12 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2009 | 107 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2008 | 24 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 306 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2009 | 89 | 0.080 |
Why?
|
| China | 2 | 2000 | 138 | 0.080 |
Why?
|
| Chromosome Disorders | 1 | 2008 | 31 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 35 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2009 | 132 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 334 | 0.080 |
Why?
|
| Drug Carriers | 2 | 1999 | 90 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 2 | 2006 | 72 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 159 | 0.080 |
Why?
|
| Genomics | 1 | 2009 | 168 | 0.080 |
Why?
|
| Age of Onset | 1 | 2008 | 188 | 0.080 |
Why?
|
| Adipokines | 1 | 2007 | 20 | 0.080 |
Why?
|
| England | 2 | 2005 | 64 | 0.080 |
Why?
|
| Health Care Rationing | 1 | 2008 | 32 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2009 | 328 | 0.080 |
Why?
|
| Ischemic Attack, Transient | 1 | 2009 | 167 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 121 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 411 | 0.070 |
Why?
|
| Splenic Rupture | 1 | 2007 | 5 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 291 | 0.070 |
Why?
|
| Sampling Studies | 2 | 1999 | 80 | 0.070 |
Why?
|
| Environment | 1 | 2008 | 115 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2005 | 88 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 329 | 0.070 |
Why?
|
| Consumer Product Safety | 1 | 2007 | 32 | 0.070 |
Why?
|
| Zygomycosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2007 | 97 | 0.070 |
Why?
|
| Demography | 3 | 2004 | 279 | 0.070 |
Why?
|
| North Carolina | 2 | 1999 | 224 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 24 | 0.070 |
Why?
|
| Hematocrit | 1 | 2007 | 70 | 0.070 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1986 | 4 | 0.070 |
Why?
|
| Lung Injury | 1 | 2007 | 38 | 0.070 |
Why?
|
| Multifunctional Enzymes | 1 | 2006 | 2 | 0.070 |
Why?
|
| Inservice Training | 1 | 2007 | 68 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2008 | 159 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2007 | 52 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2006 | 15 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 10 | 0.070 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2006 | 9 | 0.070 |
Why?
|
| Triazoles | 1 | 2007 | 43 | 0.070 |
Why?
|
| Thrombopoietin | 1 | 2006 | 15 | 0.070 |
Why?
|
| Insurance, Hospitalization | 2 | 1997 | 6 | 0.070 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2006 | 9 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2009 | 191 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 1995 | 1738 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2007 | 94 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 19 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 3 | 1998 | 219 | 0.070 |
Why?
|
| Anemia, Hypochromic | 1 | 2006 | 3 | 0.070 |
Why?
|
| Hyponatremia | 1 | 1986 | 20 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 122 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 137 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 40 | 0.070 |
Why?
|
| DNA Helicases | 1 | 2006 | 64 | 0.070 |
Why?
|
| Stereotyping | 1 | 2006 | 20 | 0.070 |
Why?
|
| Biopsy | 2 | 2007 | 540 | 0.070 |
Why?
|
| Orbital Neoplasms | 1 | 1986 | 21 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2007 | 122 | 0.070 |
Why?
|
| Comprehension | 1 | 2006 | 71 | 0.070 |
Why?
|
| Management Information Systems | 1 | 2005 | 4 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2006 | 55 | 0.070 |
Why?
|
| Symptom Assessment | 2 | 2018 | 33 | 0.070 |
Why?
|
| Quinine | 1 | 2005 | 8 | 0.070 |
Why?
|
| Boston | 1 | 2005 | 35 | 0.070 |
Why?
|
| Insurance Claim Reporting | 1 | 2005 | 10 | 0.070 |
Why?
|
| Mitomycin | 1 | 2005 | 27 | 0.070 |
Why?
|
| Calcium | 1 | 2010 | 929 | 0.070 |
Why?
|
| Random Allocation | 3 | 2005 | 442 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 1996 | 109 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2006 | 199 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2007 | 175 | 0.060 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2005 | 12 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 597 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 1986 | 241 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 572 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2006 | 99 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 125 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 35 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 45 | 0.060 |
Why?
|
| Cardiac Catheterization | 2 | 2003 | 419 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 121 | 0.060 |
Why?
|
| Midwestern United States | 1 | 2005 | 36 | 0.060 |
Why?
|
| Endostatins | 1 | 2004 | 11 | 0.060 |
Why?
|
| Mastectomy, Segmental | 2 | 2004 | 64 | 0.060 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2005 | 37 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 47 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2007 | 546 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2004 | 49 | 0.060 |
Why?
|
| Sexuality | 1 | 2004 | 12 | 0.060 |
Why?
|
| Paris | 2 | 1994 | 3 | 0.060 |
Why?
|
| Nurse-Patient Relations | 2 | 2015 | 34 | 0.060 |
Why?
|
| Papanicolaou Test | 2 | 2002 | 54 | 0.060 |
Why?
|
| Vaginal Smears | 2 | 2002 | 79 | 0.060 |
Why?
|
| Nausea | 1 | 2004 | 47 | 0.060 |
Why?
|
| Hemoglobinometry | 1 | 2004 | 5 | 0.060 |
Why?
|
| Blood Transfusion | 3 | 2008 | 205 | 0.060 |
Why?
|
| Topotecan | 1 | 2004 | 17 | 0.060 |
Why?
|
| Vomiting | 1 | 2004 | 56 | 0.060 |
Why?
|
| Social Support | 2 | 2005 | 423 | 0.060 |
Why?
|
| Causality | 1 | 2004 | 82 | 0.060 |
Why?
|
| Gastrectomy | 1 | 2003 | 24 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 371 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 472 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 68 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 183 | 0.060 |
Why?
|
| Weight Gain | 1 | 2004 | 135 | 0.060 |
Why?
|
| Cytokines | 1 | 2007 | 866 | 0.060 |
Why?
|
| Income | 1 | 2004 | 167 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 64 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2009 | 665 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2005 | 313 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 1997 | 1054 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2006 | 98 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 626 | 0.050 |
Why?
|
| Communication | 1 | 2005 | 329 | 0.050 |
Why?
|
| Palliative Care | 1 | 2004 | 271 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 206 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2002 | 122 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2014 | 32 | 0.050 |
Why?
|
| Hospital Costs | 2 | 1999 | 117 | 0.050 |
Why?
|
| Steroids | 1 | 2002 | 84 | 0.050 |
Why?
|
| Reverse Transcription | 1 | 2021 | 3 | 0.050 |
Why?
|
| Retroelements | 1 | 2021 | 4 | 0.050 |
Why?
|
| Universal Precautions | 1 | 2001 | 5 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2001 | 35 | 0.050 |
Why?
|
| Sex Education | 1 | 2001 | 20 | 0.050 |
Why?
|
| Radiation-Protective Agents | 1 | 2001 | 16 | 0.050 |
Why?
|
| Sinusitis | 1 | 1986 | 432 | 0.050 |
Why?
|
| Radiation Oncologists | 1 | 2020 | 1 | 0.050 |
Why?
|
| Political Systems | 1 | 2000 | 2 | 0.050 |
Why?
|
| Testicular Diseases | 1 | 2000 | 1 | 0.050 |
Why?
|
| Epithelium | 1 | 2021 | 172 | 0.050 |
Why?
|
| Total Quality Management | 1 | 2001 | 45 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2020 | 16 | 0.050 |
Why?
|
| Muscle Cells | 1 | 2020 | 30 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 20 | 0.050 |
Why?
|
| Prednisone | 2 | 2014 | 104 | 0.050 |
Why?
|
| Group Purchasing | 1 | 2000 | 1 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 125 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2021 | 251 | 0.050 |
Why?
|
| Cyclophosphamide | 3 | 2011 | 129 | 0.050 |
Why?
|
| Prostatitis | 1 | 2000 | 10 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2000 | 11 | 0.050 |
Why?
|
| Uncertainty | 1 | 2000 | 31 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2021 | 155 | 0.050 |
Why?
|
| Nurse's Role | 1 | 2001 | 66 | 0.050 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2001 | 40 | 0.050 |
Why?
|
| Dissection | 1 | 2020 | 29 | 0.050 |
Why?
|
| Global Health | 1 | 2001 | 136 | 0.040 |
Why?
|
| Diethylstilbestrol | 1 | 2000 | 45 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2020 | 81 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2000 | 86 | 0.040 |
Why?
|
| Heart Failure | 1 | 2009 | 1180 | 0.040 |
Why?
|
| Adipocytes | 1 | 2020 | 88 | 0.040 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2000 | 9 | 0.040 |
Why?
|
| Cost Control | 1 | 2000 | 34 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2000 | 117 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2000 | 164 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 2003 | 154 | 0.040 |
Why?
|
| Public Policy | 1 | 2000 | 71 | 0.040 |
Why?
|
| Publication Bias | 1 | 1999 | 8 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 33 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2000 | 26 | 0.040 |
Why?
|
| Nebraska | 1 | 1999 | 9 | 0.040 |
Why?
|
| Taiwan | 2 | 1996 | 20 | 0.040 |
Why?
|
| Coinfection | 1 | 2019 | 30 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2019 | 16 | 0.040 |
Why?
|
| Aortic Rupture | 1 | 2019 | 32 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1992 | 23 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 1999 | 34 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2000 | 190 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 63 | 0.040 |
Why?
|
| Risk Sharing, Financial | 1 | 1999 | 1 | 0.040 |
Why?
|
| Practice Valuation and Purchase | 1 | 1999 | 1 | 0.040 |
Why?
|
| Virus Replication | 1 | 2019 | 104 | 0.040 |
Why?
|
| Sweden | 1 | 1999 | 21 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 1999 | 145 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 1999 | 79 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 1999 | 201 | 0.040 |
Why?
|
| Linear Models | 2 | 2012 | 521 | 0.040 |
Why?
|
| Myotomy | 1 | 2018 | 14 | 0.040 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 18 | 0.040 |
Why?
|
| Esophagoscopy | 1 | 2018 | 72 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 86 | 0.040 |
Why?
|
| Leukocytes | 2 | 2000 | 99 | 0.040 |
Why?
|
| ROC Curve | 1 | 1999 | 392 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 1998 | 18 | 0.040 |
Why?
|
| Dilatation | 1 | 2018 | 58 | 0.040 |
Why?
|
| Sclerosing Solutions | 1 | 1998 | 6 | 0.040 |
Why?
|
| Platelet Count | 1 | 1998 | 100 | 0.040 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1998 | 8 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1998 | 22 | 0.040 |
Why?
|
| Zidovudine | 1 | 1998 | 27 | 0.040 |
Why?
|
| Medical Errors | 1 | 2018 | 80 | 0.040 |
Why?
|
| Models, Psychological | 1 | 1999 | 180 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2003 | 448 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 1083 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 1998 | 64 | 0.040 |
Why?
|
| Hospitals, Municipal | 1 | 1997 | 2 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1997 | 20 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 901 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 298 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 839 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 1997 | 53 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 1447 | 0.040 |
Why?
|
| Leukemia | 1 | 1998 | 117 | 0.040 |
Why?
|
| Sample Size | 1 | 1997 | 79 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 182 | 0.040 |
Why?
|
| Amphotericin B | 2 | 2007 | 26 | 0.040 |
Why?
|
| Advance Care Planning | 1 | 1997 | 11 | 0.040 |
Why?
|
| Hospitals, County | 1 | 1996 | 6 | 0.040 |
Why?
|
| Utilization Review | 1 | 1996 | 48 | 0.040 |
Why?
|
| Malaysia | 1 | 1996 | 6 | 0.030 |
Why?
|
| Singapore | 1 | 1996 | 7 | 0.030 |
Why?
|
| Naphthoquinones | 1 | 1996 | 14 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 1998 | 319 | 0.030 |
Why?
|
| Value of Life | 1 | 1996 | 14 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 1996 | 11 | 0.030 |
Why?
|
| Financing, Organized | 1 | 1996 | 21 | 0.030 |
Why?
|
| Information Services | 1 | 1996 | 22 | 0.030 |
Why?
|
| Levonorgestrel | 1 | 2015 | 6 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 1998 | 166 | 0.030 |
Why?
|
| Population Dynamics | 1 | 1996 | 30 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2015 | 16 | 0.030 |
Why?
|
| HTLV-II Infections | 2 | 1993 | 2 | 0.030 |
Why?
|
| HTLV-I Infections | 2 | 1993 | 3 | 0.030 |
Why?
|
| Crack Cocaine | 1 | 1995 | 20 | 0.030 |
Why?
|
| Trimetrexate | 1 | 1995 | 4 | 0.030 |
Why?
|
| Homosexuality | 1 | 1995 | 10 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 8474 | 0.030 |
Why?
|
| Bisexuality | 1 | 1995 | 18 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 1996 | 183 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 1995 | 34 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 111 | 0.030 |
Why?
|
| Abiraterone Acetate | 1 | 2014 | 2 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1995 | 96 | 0.030 |
Why?
|
| Finland | 1 | 1994 | 13 | 0.030 |
Why?
|
| Androstadienes | 1 | 2014 | 41 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1994 | 219 | 0.030 |
Why?
|
| New York | 1 | 1994 | 223 | 0.030 |
Why?
|
| Utah | 1 | 1993 | 27 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 2791 | 0.030 |
Why?
|
| Deltaretrovirus Antibodies | 1 | 1993 | 1 | 0.030 |
Why?
|
| Deltaretrovirus Infections | 1 | 1993 | 3 | 0.030 |
Why?
|
| Antibodies | 2 | 2005 | 241 | 0.030 |
Why?
|
| Workload | 1 | 1995 | 103 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2013 | 111 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1993 | 46 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 80 | 0.030 |
Why?
|
| Austria | 1 | 1993 | 17 | 0.030 |
Why?
|
| National Health Programs | 1 | 1993 | 11 | 0.030 |
Why?
|
| DNA Primers | 1 | 1993 | 302 | 0.030 |
Why?
|
| Private Practice | 1 | 1993 | 19 | 0.030 |
Why?
|
| Fees, Medical | 1 | 1993 | 9 | 0.030 |
Why?
|
| Transcultural Nursing | 1 | 1993 | 8 | 0.030 |
Why?
|
| Urban Population | 1 | 1994 | 255 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 376 | 0.030 |
Why?
|
| Alleles | 1 | 1993 | 386 | 0.030 |
Why?
|
| Biohazard Release | 1 | 2012 | 1 | 0.030 |
Why?
|
| Family | 1 | 1995 | 293 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 54 | 0.030 |
Why?
|
| Women | 1 | 1993 | 40 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 164 | 0.030 |
Why?
|
| Bacillus anthracis | 1 | 2012 | 11 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 492 | 0.030 |
Why?
|
| Video Recording | 1 | 2013 | 145 | 0.030 |
Why?
|
| Organ Size | 1 | 2013 | 242 | 0.030 |
Why?
|
| Continuity of Patient Care | 2 | 2009 | 170 | 0.030 |
Why?
|
| HTLV-I Antibodies | 1 | 1992 | 2 | 0.030 |
Why?
|
| HTLV-II Antibodies | 1 | 1992 | 2 | 0.030 |
Why?
|
| Blindness | 1 | 2012 | 22 | 0.030 |
Why?
|
| Unemployment | 1 | 1992 | 18 | 0.030 |
Why?
|
| Base Sequence | 1 | 1993 | 1015 | 0.030 |
Why?
|
| Asia | 1 | 1992 | 59 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 189 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 209 | 0.020 |
Why?
|
| DNA | 1 | 1993 | 597 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 17 | 0.020 |
Why?
|
| Aging | 1 | 1996 | 911 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2010 | 14 | 0.020 |
Why?
|
| Body Mass Index | 1 | 1993 | 867 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2011 | 88 | 0.020 |
Why?
|
| Embolism | 1 | 2010 | 45 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2013 | 374 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1034 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 1987 | 166 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1174 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2009 | 28 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 216 | 0.020 |
Why?
|
| Social Justice | 1 | 2009 | 32 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 52 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2008 | 45 | 0.020 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2007 | 5 | 0.020 |
Why?
|
| Resistin | 1 | 2007 | 9 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1993 | 657 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 71 | 0.020 |
Why?
|
| Fasting | 1 | 2007 | 75 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 2 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1987 | 5 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 196 | 0.020 |
Why?
|
| Adiponectin | 1 | 2007 | 52 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1993 | 1451 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.020 |
Why?
|
| Voriconazole | 1 | 2007 | 11 | 0.020 |
Why?
|
| Bleomycin | 1 | 2007 | 67 | 0.020 |
Why?
|
| Maxillary Sinus | 1 | 1986 | 12 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1986 | 10 | 0.020 |
Why?
|
| Patient Discharge | 1 | 1989 | 294 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1641 | 0.020 |
Why?
|
| Debridement | 1 | 1986 | 55 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1986 | 47 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1986 | 32 | 0.020 |
Why?
|
| Immunotoxins | 1 | 2006 | 23 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2006 | 18 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2007 | 172 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2003 | 258 | 0.020 |
Why?
|
| Vincristine | 1 | 1986 | 44 | 0.020 |
Why?
|
| Leucovorin | 1 | 1986 | 35 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 160 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2007 | 66 | 0.020 |
Why?
|
| Cytarabine | 1 | 1986 | 44 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 274 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2007 | 330 | 0.020 |
Why?
|
| Neutrophils | 1 | 2007 | 204 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 58 | 0.020 |
Why?
|
| Methotrexate | 1 | 1986 | 91 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2005 | 8 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 5300 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1986 | 168 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1986 | 100 | 0.020 |
Why?
|
| Medication Systems, Hospital | 1 | 2005 | 19 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2005 | 55 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2004 | 54 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2006 | 254 | 0.020 |
Why?
|
| Insulin | 1 | 2007 | 619 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 174 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 301 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2004 | 34 | 0.010 |
Why?
|
| Mastectomy | 1 | 2004 | 57 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2005 | 369 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2003 | 26 | 0.010 |
Why?
|
| Capillaries | 1 | 2003 | 105 | 0.010 |
Why?
|
| Radioimmunoprecipitation Assay | 2 | 1993 | 5 | 0.010 |
Why?
|
| Urban Health | 1 | 2003 | 49 | 0.010 |
Why?
|
| Rural Health | 1 | 2003 | 66 | 0.010 |
Why?
|
| False Negative Reactions | 2 | 1993 | 63 | 0.010 |
Why?
|
| Observation | 1 | 2002 | 30 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 369 | 0.010 |
Why?
|
| Markov Chains | 1 | 2002 | 133 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2003 | 123 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 507 | 0.010 |
Why?
|
| Ohio | 1 | 2000 | 64 | 0.010 |
Why?
|
| Body Fluids | 1 | 2000 | 41 | 0.010 |
Why?
|
| Obesity | 1 | 2007 | 1076 | 0.010 |
Why?
|
| Delphi Technique | 1 | 2000 | 62 | 0.010 |
Why?
|
| Ventilation | 1 | 2000 | 3 | 0.010 |
Why?
|
| Awareness | 1 | 2000 | 81 | 0.010 |
Why?
|
| Sports | 1 | 2000 | 55 | 0.010 |
Why?
|
| Tuberculin Test | 1 | 2000 | 16 | 0.010 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2000 | 18 | 0.010 |
Why?
|
| Busulfan | 1 | 1999 | 13 | 0.010 |
Why?
|
| Goserelin | 1 | 1999 | 6 | 0.010 |
Why?
|
| Schools | 1 | 2000 | 156 | 0.010 |
Why?
|
| APACHE | 1 | 1998 | 41 | 0.010 |
Why?
|
| Internet | 1 | 2000 | 390 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2324 | 0.010 |
Why?
|
| Atovaquone | 1 | 1996 | 2 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1996 | 1 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1996 | 9 | 0.010 |
Why?
|
| Hepatitis B Antibodies | 1 | 1996 | 8 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1996 | 24 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1996 | 41 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1996 | 25 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1996 | 35 | 0.010 |
Why?
|
| Carrier State | 1 | 1996 | 39 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 1996 | 124 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1996 | 97 | 0.010 |
Why?
|
| Critical Illness | 1 | 1995 | 191 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1996 | 311 | 0.010 |
Why?
|
| San Francisco | 1 | 1993 | 3 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 164 | 0.010 |
Why?
|
| Carmustine | 1 | 1993 | 14 | 0.010 |
Why?
|
| Etoposide | 1 | 1993 | 64 | 0.010 |
Why?
|
| Acculturation | 1 | 1993 | 25 | 0.010 |
Why?
|
| Czechoslovakia | 1 | 1992 | 1 | 0.010 |
Why?
|
| Environmental Pollution | 1 | 1992 | 25 | 0.010 |
Why?
|
| HTLV-I Antigens | 1 | 1992 | 1 | 0.010 |
Why?
|
| HTLV-II Antigens | 1 | 1992 | 1 | 0.010 |
Why?
|
| Agglutination Tests | 1 | 1992 | 9 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1992 | 11 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1990 | 50 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 1990 | 38 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1990 | 112 | 0.010 |
Why?
|
| Heart Atria | 1 | 1990 | 206 | 0.010 |
Why?
|
| Sepsis | 1 | 1990 | 233 | 0.000 |
Why?
|